<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neostigmine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neostigmine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Neostigmine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11397" href="/d/html/11397.html" rel="external">see "Neostigmine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12640" href="/d/html/12640.html" rel="external">see "Neostigmine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F200742"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bloxiverz</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867666"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Neostigmine Omega;</li>
<li>Prostigmin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F200781"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F200746"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2f44fbb-0d9f-46cf-b3aa-8b6dff0265c7">Myasthenia gravis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, treatment:</b>
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15 mg administered 3 times daily. Usual daily dose: 150 mg/day in divided doses; interval between doses should be adjusted per patient response with larger doses provided at times of most fatigue. Usual daily dosage range: 15 to 375 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de02ec1d-a835-4256-83d1-aabf2d6d6b94">Reversal of nondepolarizing neuromuscular blockade after surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blockade after surgery:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given intravenously prior to (if patient is bradycardic) or in conjunction with neostigmine (to prevent bradycardia and GI symptoms). Avoid use or use with caution in patients with certain neuromuscular diseases (eg, myasthenia gravis, muscular dystrophy); other agents may be preferred (eg, sugammadex); if neostigmine is used, reduced dosing may be required with titration based on train-of-four (TOF) monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Balaka.1','lexi-content-ref-12911205','lexi-content-ref-7073921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Balaka.1','lexi-content-ref-12911205','lexi-content-ref-7073921'])">Ref</a></span>). TOF monitoring should be used to determine time of neostigmine initiation and need for additional doses. Dosing may vary depending on patient specific factors (eg, depth of paralysis, type of anesthesia, organ dysfunction, age, acid-base status) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gropper.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gropper.1'])">Ref</a></span>). Refer to institutional protocols and policies.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual dose:</i>
<b>IV: </b>0.02 to 0.07 mg/kg; generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gropper.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gropper.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose selection based on TOF count at end of surgery</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gropper.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gropper.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">TOF count 1 or no TOF response: Delay reversal until TOF count ≥2.</p>
<p style="text-indent:-2em;margin-left:8em;">TOF count 2 or 3: 0.07 mg/kg; allow at least 15 to 30 minutes before tracheal extubation.</p>
<p style="text-indent:-2em;margin-left:8em;">TOF count 4 with observable fade: 0.04 to 0.05 mg/kg; allow at least 10 to 15 minutes before tracheal extubation.</p>
<p style="text-indent:-2em;margin-left:8em;">TOF count 4 with no observable fade: 0.02 mg/kg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37657258-cda9-424f-9e89-34851117b532">Acute colonic pseudo-obstruction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute colonic pseudo-obstruction (Ogilvie syndrome) (off-label use): Note:</b> Continuous cardiac monitoring with clinical assessment for 30 minutes after administration. Atropine should be available at the bedside if bradyarrhythmia occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16268965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16268965'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bolus: <b>IV: </b>2 mg over 3 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11270887','lexi-content-ref-10638606','lexi-content-ref-10403850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11270887','lexi-content-ref-10638606','lexi-content-ref-10403850'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion: <b>IV:</b> 2.5 mg over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10703857','lexi-content-ref-9369112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10703857','lexi-content-ref-9369112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV:</b> 0.4 mg per hour for up to 8 hours; if no response increase to 0.8 mg per hour for up to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30541715','lexi-content-ref-25568788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30541715','lexi-content-ref-25568788'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990824"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in manufacturer's labeling. The manufacturer recommends close monitoring in patients with impaired renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 10 to 50 mL/minute: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;10 mL/minute: Administer 25% of normal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous renal replacement therapy (CRRT): Administer 50% of normal dose</p></div>
<div class="block doha drugH1Div" id="F50988035"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; has not been studied.</p></div>
<div class="block doe drugH1Div" id="F200747"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F200763"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12640" href="/d/html/12640.html" rel="external">see "Neostigmine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0a8a050-cc71-45aa-bc5d-3cac3c9c461a">Myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Myasthenia gravis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Diagnosis:</i>
<b> Note:</b> Pretreatment with atropine is recommended, and atropine should be available. IV fluids also recommended. Children &lt;2 years: IM: 0.04 mg/kg once; if results equivocal or negative, may be repeated once in 4 hours. Typical dose is 0.5 to 1.5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i>
<b> Note:</b> Dosage requirements are variable; dosage should be individualized: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 0.3 to 2 mg/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23117946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23117946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">IM, IV, SubQ: 0.01 to 0.04 mg/kg every 2 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-Kliegman.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de02ec1d-a835-4256-83d1-aabf2d6d6b94">Reversal of nondepolarizing neuromuscular blockade after surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Reversal of nondepolarizing neuromuscular blockade after surgery:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer labeling: Bloxiverz: <b>Note:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior to neostigmine. Peripheral nerve stimulation delivering train-of-four (TOF) stimulus must also be used to determine time of neostigmine initiation and need for additional doses.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Usual dose:</i> 0.03 to 0.07 mg/kg generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose selection guide: </i></p>
<p style="text-indent:-2em;margin-left:10em;">The 0.03 mg/kg dose is recommended for reversal of NMBAs with shorter half-lives (eg, rocuronium); or when the first twitch response to the TOF stimulus is substantially &gt;10% of baseline or when a second twitch is present.</p>
<p style="text-indent:-2em;margin-left:10em;">The 0.07 mg/kg dose is recommended for NMBAs with longer half-lives (eg, vecuronium, pancuronium); or when the first twitch response is relatively weak (ie, not substantially &gt;10% of baseline); or rapid recovery is needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate dosing: Generic injectable products: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007','lexi-content-ref-Nelson.1996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007','lexi-content-ref-Nelson.1996'])">Ref</a></span>): Infants and Children: 0.025 to 0.1 mg/kg/dose</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51130769"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F200716"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block, cardiac arrhythmia (including atrioventricular nodal arrhythmia, bradycardia [Ruetzler 2022], tachycardia), flushing, hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence, increased peristalsis, nausea, sialorrhea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Oxygen desaturation</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Ruetzler 2022), hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, dizziness, drowsiness, dysarthria, headache, insomnia, loss of consciousness, postanesthetic shivering, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Miosis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, bronchospasm (Ruetzler 2022), dyspnea, increased bronchial secretions (including pharyngeal secretions), respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG changes (nonspecific)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Fasciculations</p></div>
<div class="block coi drugH1Div" id="F200728"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to neostigmine or any component of the formulation; peritonitis or mechanical obstruction of the intestinal or urinary tract.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (tablets only):</i> Additional contraindications (not in US labeling): Hypersensitivity to bromides.</p></div>
<div class="block war drugH1Div" id="F200714"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Bradycardia, hypotension, and dysrhythmias may occur, particularly with IV use; risk may be increased in patients with certain cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome). Risk may also be increased in patients with myasthenia gravis. When IV neostigmine is administered for the reversal of nondepolarizing neuromuscular-blocking agents, atropine or glycopyrrolate should be administered concurrently or prior to neostigmine to lessen the risk of bradycardia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholinergic crisis: Overdosage may result in cholinergic crisis, characterized by extreme muscle weakness and potentially fatal respiratory paralysis. Cholinergic crisis should be distinguished from myasthenic crisis, which is also characterized by extreme muscle weakness, but would require radically different treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Symptoms of hypersensitivity have included anaphylaxis, angioedema, bradycardia, bronchospasm, erythema multiforme, facial swelling, flushing, generalized rash, hypotension, peripheral edema, pyrexia, and urticaria. Have atropine and epinephrine ready to treat hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular effects: Large doses of IV neostigmine administered for the reversal of nondepolarizing neuromuscular-blocking agents when neuromuscular blockade is minimal can result in neuromuscular dysfunction. Reduce dose if recovery from neuromuscular blockade is nearly complete.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use with caution in patients with asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with bradycardia, cardiac arrhythmias, coronary artery disease, or recent acute coronary syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Megacolon/GI dysfunction: Large oral doses should be avoided with megacolon or decreased GI motility. Neostigmine may accumulate; toxicity may result when motility is restored.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular diseases: For reversal of nondepolarizing neuromuscular blockade, avoid use or use with caution in patients with certain neuromuscular diseases (eg, myasthenia gravis, muscular dystrophy); other agents may be preferred (eg, sugammadex); if used, reduced dosing may be required with titration based on train-of-four monitoring (Balaka 2011; Briggs 2003; Buzello 1982). Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with epilepsy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vagotonia: Use with caution in patients with vagotonia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: When used IV for the reversal of nondepolarizing muscle relaxants, pediatric and adult dosing is similar. However, recovery may be more rapid and risk of complications may be greater in infants and small children. Monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution and monitor for a longer period. Elderly patients experience slower spontaneous recovery from neuromuscular blocking agents.</p></div>
<div class="block foc drugH1Div" id="F200722"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as methylsulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bloxiverz: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL) [contains phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous, as methylsulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 mg/3 mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F200710"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323488"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bloxiverz Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/10 mL (per mL): $2.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $2.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neostigmine Methylsulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/10 mL (per mL): $0.72 - $3.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $0.72 - $3.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Neostigmine Methylsulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/3 mL (per mL): $6.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867667"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as methylsulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/mL (1 mL, 10 mL); 1 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prostigmin: 15 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F200725"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Tablets (neostigmine bromide): Prostigmin [Canadian product]: Muscarinic effects may be decreased when administered with food or milk. Consider giving larger portions of the daily dose around fatigue prone times (eg, mealtimes, afternoons).</p>
<p style="text-indent:-2em;margin-left:2em;">Injectable (neostigmine methylsulfate):</p>
<p style="text-indent:-2em;margin-left:4em;">Neostigmine Omega, Prostigmin [Canadian products]: May be administered IM, IV, or SUBQ.</p>
<p style="text-indent:-2em;margin-left:4em;">Bloxiverz: Administer by slow IV injection over at least 1 minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Acute colonic pseudo-obstruction (off-label use):</p>
<p style="text-indent:-2em;margin-left:4em;">Bolus: IV: Administer over 3 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10403850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10403850'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion: IV: Administration over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10703857','lexi-content-ref-9369112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10703857','lexi-content-ref-9369112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: IV: Refer to indication-specific infusion rates in "Dosing: Adult" for detailed recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30541715','lexi-content-ref-25568788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30541715','lexi-content-ref-25568788'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613409"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Parenteral: May be administered undiluted by slow IV injection over several minutes; may be administered IM or SubQ </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral: Divide dosages so patient receives larger doses at times of greatest fatigue; may be administered with or without food</p></div>
<div class="block use drugH1Div" id="F200724"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>US labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Reversal of nondepolarizing muscle relaxants:</b> Reversal of effects of nondepolarizing neuromuscular blocking agents after surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Canadian labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Myasthenia gravis:</b> Symptomatic control of myasthenia gravis (oral product).</p>
<p style="text-indent:-2em;margin-left:6em;">Limitations of use: Other agents may be preferred for symptomatic treatment or acute exacerbations.</p></div>
<div class="block off-label drugH1Div" id="F27254532"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute colonic pseudo-obstruction (Ogilvie’s syndrome)</p></div>
<div class="block mst drugH1Div" id="F200789"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bloxiverz may be confused with Vazculep (phenylephrine injection) due to similar packaging</p>
<p style="text-indent:-2em;margin-left:4em;">Prostigmin may be confused with physostigmine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299756"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F200718"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: Neostigmine may diminish the therapeutic effect of Kanamycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13855370"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies (doses used were below maximum expected human exposure based on BSA).</p>
<p style="text-indent:0em;margin-top:2em;">When used as adjunct to analgesia in labor, adverse events to the fetus and mother are dose- and route-dependent (Habib 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Neostigmine may be used to treat myasthenia gravis in pregnant patients; however, if an acetylcholinesterase inhibitor is needed during pregnancy, another agent may be preferred (Sanders 2016).</p></div>
<div class="block brc drugH1Div" id="F20617175"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if neostigmine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F21285938"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">ECG, blood pressure, and heart rate especially with IV use; train-of-four monitoring; consult individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Acute colonic pseudo-obstruction (off-label use): Keep patient supine upon administration. Patient should receive continuous ECG monitoring with clinical assessment for 30 minutes after administration (Saunders 2005).</p></div>
<div class="block pha drugH1Div" id="F200713"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction; direct cholinomimetic effect on skeletal muscle and possible on autonomic ganglion cells and neurons of the CNS</p></div>
<div class="block phk drugH1Div" id="F200727"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Peristaltic activity: Oral: 2 to 4 hours; Parenteral: 10 to 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM: 2.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Poor (~1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 0.12 to 1.4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 15% to 25% to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Adults: 51 to 90 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Range: 24 to 113 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 2 to 10 months: Mean: 39 ± 5 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 6 years: Mean: 48 ± 16 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Adults 29 to 48 years: 67 ± 8 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Anephric patients: 181 ± 54 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Renal transplant recipients: 104.7 ± 64 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Adults: 42 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: 1 to 2 hours (Aquilonius 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% as unchanged drug; remainder as metabolites) (Aquilonius 1986)</p></div>
<div class="block phksp drugH1Div" id="F51154890"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life prolonged in anephric patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F200731"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Normastigmin | Prostigmin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Neostigmina Bromuro | Prostigmine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine br.</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Neoeserin | Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Intrastigmina | Prostigmine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Neostigmine methylsulfate | Proserin | Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amostigmine | Neostigmine | Prostigmine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Metastigmin | Neostigmin | Neostigmin fortior</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine Opi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Neostigmina lph | Neostigmine | Prostigmine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin | Stigmosan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine | Prostigmin | Tyzox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Tilstigmin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Intrastigmina | Prostigmina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Neostigmina lph | Proserin | Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Proserin | Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Neostigmina | Prostigmine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Neomin | Neostigmine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine | Prostigmin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Polstigminum | Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine methylsulfate | Prostigmin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Epistigmin | Prostigmin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Proserin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine | Prostigmine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Neostigmine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prostigmin | Syntostigmin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Prostigmine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Neostigmin | Neostigmine | Neostimin | Prostigmin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Proserin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Prostigmine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11270887">
<a name="11270887"></a>Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. <i>Am Surg</i>. 2001;67(3):265-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/11270887/pubmed" id="11270887" target="_blank">11270887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10638606">
<a name="10638606"></a>Amaro R, Rogers AI. Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? <i>Am J Gastroenterol</i>. 2000;95(1):304-305. doi:10.1111/j.1572-0241.2000.01737.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10638606/pubmed" id="10638606" target="_blank">10638606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3524957">
<a name="3524957"></a>Aquilonius SM, Hartviq P. Clinical pharmacokinetics of cholinesterase inhibitors. <i>Clin Pharmacokinet</i>. 1986;11(3):236-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/3524957/pubmed" id="3524957" target="_blank">3524957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Balaka.1">
<a name="Balaka.1"></a>Balaka C, Poulida S, Miliatou M, et al. Comparison of sugammadex to neostigmine reversal of neuromuscular blockade in patients with myasthenia gravis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i>. 2011;25:S22-S23.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bloxiverz.1">
<a name="Bloxiverz.1"></a>Bloxiverz (neostigmine) [prescribing information]. Lenoir, NC: Exela Pharma Sciences LLC; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12911205">
<a name="12911205"></a>Briggs ED, Kirsch JR. Anesthetic implications of neuromuscular disease. <i>J Anesth</i>. 2003;17(3):177-185. doi:10.1007/s00540-003-0169-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/12911205/pubmed" id="12911205" target="_blank">12911205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7073921">
<a name="7073921"></a>Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. <i>Br J Anaesth.G</i> 1982;54(5):529-534. doi:10.1093/bja/54.5.529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/7073921/pubmed" id="7073921" target="_blank">7073921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M. Qualitative monitoring used (peripheral nerve stimulator). <i>Miller's Anaesth</i>. 2019;1(9):3170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16999453">
<a name="16999453"></a>Habib AS and Gan TJ, "Use of Neostigmine in the Management of Acute Postoperative Pain and Labour Pain: A Review," <i>CNS Drugs</i>, 2006, 20(10):821-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/16999453/pubmed" id="16999453" target="_blank">16999453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30541715">
<a name="30541715"></a>İlban Ö, Çiçekçi F, Çelik JB, Baş MA, Duman A. Neostigmine treatment protocols applied in acute colonic pseudo-obstruction disease: a retrospective comparative study. <i>Turk J Gastroenterol</i>. 2019;30(3):228-233. doi:10.5152/tjg.2018.18193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/30541715/pubmed" id="30541715" target="_blank">30541715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neostigmine.1">
<a name="Neostigmine.1"></a>Neostigmine Omega (neostigmine) [product monograph]. Montreal, Quebec, Canada: Omega Laboratories Limited; May 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neostigmine.2">
<a name="Neostigmine.2"></a>Neostigmine injection [prescribing information]. Eatontown, NJ: West Ward Pharmaceuticals; October 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neostigmine.3">
<a name="Neostigmine.3"></a>Neostigmine Methylsulfate Injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10703857">
<a name="10703857"></a>Paran H, Silverberg D, Mayo A, Shwartz I, Neufeld D, Freund U. Treatment of acute colonic pseudo-obstruction with neostigmine. <i>J Am Coll Surg</i>. 2000;190(3):315-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10703857/pubmed" id="10703857" target="_blank">10703857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10403850">
<a name="10403850"></a>Ponec RJ, Saunders MD, and Kimmey MB, "Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction," <i>N Engl J Med</i>, 1999, 341(3):137-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10403850/pubmed" id="10403850" target="_blank">10403850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prostigmin.1">
<a name="Prostigmin.1"></a>Prostigmin (neostigmine) [product monograph]. Montreal, Quebec, Canada: Valeant Canada; June 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35020636">
<a name="35020636"></a>Ruetzler K, Li K, Chhabada S, et al. Sugammadex versus neostigmine for reversal of residual neuromuscular blocks after surgery: a retrospective cohort analysis of postoperative side effects. <i>Anesth Analg</i>. 2022;134(5):1043-1053. doi:10.1213/ANE.0000000000005842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/35020636/pubmed" id="35020636" target="_blank">35020636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358333">
<a name="27358333"></a>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. <i>Neurology</i>. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/27358333/pubmed" id="27358333" target="_blank">27358333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16268965">
<a name="16268965"></a>Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. <i>Aliment Pharmacol Ther</i>. 2005;22(10):917-925.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/16268965/pubmed" id="16268965" target="_blank">16268965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23117946">
<a name="23117946"></a>Silvestri NJ, Wolfe GI. Myasthenia gravis. <i>Semin Neurol</i>. 2012;32(3):215-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/23117946/pubmed" id="23117946" target="_blank">23117946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10826417">
<a name="10826417"></a>Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. <i>Dis Colon Rectum</i>. 2000;43(5):599-603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/10826417/pubmed" id="10826417" target="_blank">10826417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9369112">
<a name="9369112"></a>Turégano-Fuentes F, Muñoz-Jiménez F, Del Valle-Hernández E, et al. Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment. <i>Dis Colon Rectum</i>. 1997;40(11):1353-1357. doi:10.1007/BF02050822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/9369112/pubmed" id="9369112" target="_blank">9369112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25568788">
<a name="25568788"></a>Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. <i>Ann Med Surg (Lond)</i>. 2014;3(3):60-64. doi:10.1016/j.amsu.2014.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/neostigmine-drug-information/abstract-text/25568788/pubmed" id="25568788" target="_blank">25568788</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9693 Version 439.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
